Browsing by Author Rosenstock, Julio

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?Perkovic, Vlado; Broedl, Uli C; George, Jyothis T; Marx, Nikolaus; Mcguire, Darren K; Rosenstock, Julio; von Eynatten, Maximilian; Woerle, Hans-Juergen; The George Institute for Global HealthComposite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: Should unstable angina be included in the primary end point?, Diabetes Care, vol.40, 9, 2017,pp 1144-1151
2015Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled TrialFulcher, Greg; Neal, Bruce; Perkovic, Vlado; Capuano, George; de Zeeuw, Dick; Desai, Mehul; Mahaffey, Kenneth W; Matthews, David. R.; Meininger, G; Rosenstock, Julio; Shaw, Wayne; Vercruysse, Frank; Weiss, Robert; Northern Clinical School: Medicine; The George Institute for Global Health; The George Institute for Global HealthEfficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial, Diabetes Therapy, vol.6, 3, 2015,pp 289-302
2011Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial.Fulcher, Greg; Endahl, Lars; Johansen, Thue; Lewin, Andrew; Lindh, Rebecca; Mathieu, Chantal; Pinget, Michel; Rao, Paturi; Rosenstock, Julio; Thomas, Nihal; Zinman, Bernard; Northern Clinical School: MedicineInsulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial., The Lancet, vol.377, 9769, 2011,pp 924-931
2015Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 DiabetesPerkovic, Vlado; Cooper, Mark; Groop, Per-Henrik; Hehnke, Uwe; McGill, Janet B; Rosenstock, Julio; von Eynatten, Maximilian; Wanner, Christoph; Woerle, Hans-Juergen; The George Institute for Global HealthKidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes, American Journal of Kidney Diseases, vol.66, 3, 2015,pp 441-449